CoChat
Sign Up
Cited by 97Estrogen and related hormone effectsBreast Cancer Treatment StudiesUbiquitin and proteasome pathways

Regulation of estrogen signaling and breast cancer proliferation by an ubiquitin ligase TRIM56

Open access
Xue, Min, Zhang, Kai, Mu, Kun, Xu, Juntao, Yang, Huijie, Liu, Yun, Wang, Beibei, Wang, Zhonghao +6 more·2019·Oncogenesis
DOI 10.1038/s41389-019-0139-xPMC PMC6473003
Open this paper in CoChat — free accountOpen PDF

Abstract

Breast cancer ranks no. 1 in women cancer worldwide, while 60–70% are estrogen receptor alpha positive. The estrogen selective modulators, such as tamoxifen, become the effective drugs for controlling ER alpha breast cancer progression. However, tamoxifen resistance will develop during long-time treatment and cancer progression. Thus, further understanding of ER alpha signaling becomes necessary for the improvement of breast cancer therapy. Here, we identify TRIM56 as a novel regulatory factor in ER alpha signaling. TRIM56 expression is positively correlated with ER alpha and PR in breast cancer samples and is related to poor prognosis in endocrine therapy patients. TRIM56 depletion significantly decreases ER alpha signaling activity and ER-alpha-positive breast cancer proliferation in vitro and in vivo. TRIM56 associates with AF1 domain of ER alpha via its WD40 domain in the cytoplasm. TRIM56 prolongs ER alpha protein stability, possibly through targeting ER alpha K63-linked ubiquitination. In conclusion, our study reveals an interesting posttranslational mechanism between TRIM56 and ER alpha in breast cancer progression. Targeting TRIM56 could be a promising approach for ER-alpha-positive breast cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41389-019-0139-x

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

No references could be resolved yet.

Research works printed but not linked: 36

  1. [1]Reis-Filho JS Pusztai L Gene expression profiling in breast cancer: classification, prognostication, and prediction Lancet 2011 378 1812 1823 10.1016/S0140-6736(11)61539-0 22098854 · DOI
  2. [2]Rouzier R Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin. Cancer Res. 2005 11 5678 5685 10.1158/1078-0432.CCR-04-2421 16115903 · DOI
  3. [3]Onitilo AA Engel JM Greenlee RT Mukesh BN Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival Clin. Med. Res. 2009 7 4 13 10.3121/cmr.2008.825 19574486 PMC2705275 · DOI
  4. [4]Chung YL Sheu ML Yang SC Lin CH Yen SH Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer Int. J. Cancer 2002 97 306 312 10.1002/ijc.1614 11774281 · DOI
  5. [5]Massarweh S Schiff R Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk Endocr.-Relat. Cancer 2006 13 Suppl 1 S15 S24 10.1677/erc.1.01273 17259554 · DOI
  6. [6]Stoica GE Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway Oncogene 2003 22 7998 8011 10.1038/sj.onc.1206769 12970748 · DOI
  7. [7]Zhuang T SHARPIN stabilizes estrogen receptor alpha and promotes breast cancer cell proliferation Oncotarget 2017 8 77137 77151 29100376 PMC5652769
  8. [8]Wang C Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity J. Biol. Chem. 2001 276 18375 18383 10.1074/jbc.M100800200 11279135 · DOI
  9. [9]Greene GL Sequence and expression of human estrogen receptor complementary DNA Science 1986 231 1150 1154 10.1126/science.3753802 3753802 · DOI
  10. [10]Kumar R The dynamic structure of the estrogen receptor J. Amino Acids 2011 2011 812540 10.4061/2011/812540 22312471 PMC3268042 · DOI
  11. [11]Barkhem T Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists Mol. Pharmacol. 1998 54 105 112 10.1124/mol.54.1.105 9658195 · DOI
  12. [12]Wong SC Chan JK Lee KC Hsiao WL Differential expression of p16/p21/p27 and cyclin D1/D3, and their relationships to cell proliferation, apoptosis, and tumour progression in invasive ductal carcinoma of the breast J. Pathol. 2001 194 35 42 10.1002/path.838 11329139 · DOI
  13. [13]Cariou S Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells Proc. Natl Acad. Sci. USA 2000 97 9042 9046 10.1073/pnas.160016897 10908655 PMC16818 · DOI
  14. [14]Yang H SMURF1 facilitates estrogen receptor a signaling in breast cancer cells J. Exp. Clin. Cancer Res. 2018 37 24 10.1186/s13046-018-0672-z 29433542 PMC5808446 · DOI
  15. [15]Tecalco-Cruz AC Ramirez-Jarquin JO Polyubiquitination inhibition of estrogen receptor alpha and its implications in breast cancer World J. Clin. Oncol. 2018 9 60 70 10.5306/wjco.v9.i4.60 30148069 PMC6107474 · DOI
  16. [16]Zhu J The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor alpha and modulates estrogen-stimulated breast cancer cell proliferation Oncogene 2014 33 4340 4351 10.1038/onc.2013.573 24441041 PMC4141304 · DOI
  17. [17]Wang S RNF8 identified as a co-activator of estrogen receptor alpha promotes cell growth in breast cancer Biochim. et. Biophys. Acta Mol. Basis Dis. 2017 1863 1615 1628 10.1016/j.bbadis.2017.02.011 28216286 · DOI
  18. [18]Tsuchida T The ubiquitin ligase TRIM56 regulates innate immune responses to intracellular double-stranded DNA Immunity 2010 33 765 776 10.1016/j.immuni.2010.10.013 21074459 · DOI
  19. [19]Shen Y TRIM56 is an essential component of the TLR3 antiviral signaling pathway J. Biol. Chem. 2012 287 36404 36413 10.1074/jbc.M112.397075 22948160 PMC3476306 · DOI
  20. [20]Wang J TRIM56 is a virus- and interferon-inducible E3 ubiquitin ligase that restricts pestivirus infection J. Virol. 2011 85 3733 3745 10.1128/JVI.02546-10 21289118 PMC3126137 · DOI
  21. [21]Stevens TA Meech R BARX2 and estrogen receptor-alpha (ESR1) coordinately regulate the production of alternatively spliced ESR1 isoforms and control breast cancer cell growth and invasion Oncogene 2006 25 5426 5435 10.1038/sj.onc.1209529 16636675 · DOI
  22. [22]Karnik PS Kulkarni S Liu XP Budd GT Bukowski RM Estrogen receptor mutations in tamoxifen-resistant breast cancer Cancer Res. 1994 54 349 353 8275466
  23. [23]Chen JR Absence of estrogen receptor alpha (ESR1) gene amplification in a series of breast cancers in Taiwan Virchows Arch.: Int. J. Pathol. 2014 464 689 699 10.1007/s00428-014-1576-8 24756215 · DOI
  24. [24]Shou J Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer J. Natl Cancer Inst. 2004 96 926 935 10.1093/jnci/djh166 15199112 · DOI
  25. [25]Tharun IM Subtype-specific modulation of estrogen receptor-coactivator interaction by phosphorylation ACS Chem. Biol. 2015 10 475 484 10.1021/cb5007097 25386784 · DOI
  26. [26]Metzger MB Hristova VA Weissman AM HECT and RING finger families of E3 ubiquitin ligases at a glance J. Cell Sci. 2012 125 531 537 10.1242/jcs.091777 22389392 PMC3381717 · DOI
  27. [27]Deshaies RJ Joazeiro CA RING domain E3 ubiquitin ligases Annu. Rev. Biochem. 2009 78 399 434 10.1146/annurev.biochem.78.101807.093809 19489725 · DOI · Paper page
  28. [28]Eisenhaber B Chumak N Eisenhaber F Hauser MT The ring between ring fingers (RBR) protein family Genome Biol. 2007 8 209 10.1186/gb-2007-8-3-209 17367545 PMC1868946 · DOI
  29. [29]Miranda M Sorkin A Regulation of receptors and transporters by ubiquitination: new insights into surprisingly similar mechanisms Mol. Interv. 2007 7 157 167 10.1124/mi.7.3.7 17609522 · DOI
  30. [30]Sigismund S Polo S Di Fiore PP Signaling through monoubiquitination Curr. Top. Microbiol. Immunol. 2004 286 149 185 15645713
  31. [31]Seo GJ TRIM56-mediated monoubiquitination of cGAS for cytosolic DNA sensing Nat. Commun. 2018 9 613 10.1038/s41467-018-02936-3 29426904 PMC5807518 · DOI
  32. [32]Chen Y TRIM56 Suppresses Multiple Myeloma Progression by Activating TLR3/TRIF Signaling Yonsei Med. J. 2018 59 43 50 10.3349/ymj.2018.59.1.43 29214775 PMC5725363 · DOI
  33. [33]Zhao L Zhang P Su XJ Zhang B The ubiquitin ligase TRIM56 inhibits ovarian cancer progression by targeting vimentin J. Cell. Physiol. 2018 233 2420 2425 10.1002/jcp.26114 28771721 · DOI
  34. [34]Wang J Negative regulation of Nmi on virus-triggered type I IFN production by targeting IRF7 J. Immunol. 2013 191 3393 3399 10.4049/jimmunol.1300740 23956435 · DOI
  35. [35]Zhu J RING finger protein 31 promotes p53 degradation in breast cancer cells Oncogene 2016 35 1955 1964 10.1038/onc.2015.260 26148235 PMC4833873 · DOI
  36. [36]Yang H SHARPIN facilitates p53 degradation in breast cancer cells Neoplasia 2017 19 84 92 10.1016/j.neo.2016.12.002 28063307 PMC5219588 · DOI

Cited by

Sorted by citations

Authors
Xue, M., Zhang, K., Mu, K., Xu, J., Yang, H., Liu, Y., Wang, B., Wang, Z., Li, Z., Kong, Q., Li, X., Wang, H., Zhu, J., & Zhuang, T.
Affiliations
  • Henan Medical University (CN)
  • Shandong University (CN)
  • Tianjin Medical University (CN)
Corresponding author
  • Wang, Hui
  • Zhu, Jian
  • Zhuang, Ting
ORCID
Venue
Oncogenesis
Publisher
Springer Science and Business Media LLC
Published
2019-04-18
Volume
8
Issue
5
Pages
30-30
ISSN
2157-9024 (ISSN-L)
DOI
10.1038/s41389-019-0139-x
PMC
PMC6473003
OpenAlex
W2940329995
Cited by
97
References
0
Citations by year
2026: 2 · 2025: 14 · 2024: 10 · 2023: 16 · 2022: 20 · 2021: 19 · 2020: 14 · 2019: 2
FWCI
5.35
Type
journal article
Language
en
Open access
Licence
Locations
  • Oncogenesis (publishedVersion, cc-by)
  • SSRN Electronic Journal (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Science Foundation
  • National Natural Science Foundation of China (81702725, No. 81702725, U1704169)
  • Foundation of Henan Educational Committee (17A310025)
  • Henan University (15IRTSTHN025)
  • Xinxiang Medical University
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords
TRIM56, estrogen receptor alpha, breast cancer, estrogen signaling, tamoxifen resistance, protein stability, K63-linked ubiquitination, WD40 domain, progesterone receptor, endocrine therapy, tumor cell proliferation, prognostic factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review